EN ▼
Favorites
My Favorites
View All
Market Cap Price 24h%

Disclaimer: Content does not constitute investment advice. Trading involves risks—please invest with caution!

ImmunityBio, Inc. (IBRX) 股价:尽管膀胱癌治疗取得重大突破,仍下跌7.25%

2026-10-17 03:38:55
Bookmark

ImmunityBio 股价下跌,尽管临床试验结果积极

ImmunityBio, Inc. (NASDAQ: IBRX) 的股价在周五下跌了 7.25%,至 9.27 美元。尽管公司公布了膀胱癌治疗方面的重大进展,但股票仍出现下滑。股价下跌了 0.73 美元,盘中早段的一次急剧抛售导致价格在波动交易中进一步走低。与此同时,该公司发布了长期临床结果,显示难治性膀胱癌患者获得了持久的治疗反应。

ANKTIVA 试验显示出强劲的长期癌症反应

ImmunityBio 的股票在 10 月 16 日面临抛压,尽管公司宣布了令人鼓舞的临床发现。该股在全天交易中持续下跌,早盘的大幅跳水加速了其跌幅。然而,公司公布了支持其 ANKTIVA 疗法用于非肌层浸润性膀胱癌的新证据。

公司宣布发表了其二/三期 QUILT-3.032 临床试验的长期结果。《泌尿学杂志》(The Journal of Urology)刊登了这些涉及 100 名对卡介苗(BCG)无反应的膀胱癌患者的研究结果。研究人员评估了 ANKTIVA 与卡介苗疗法联合使用在治疗原位癌和某些乳头状肿瘤患者中的效果。

研究记录到接受联合治疗的患者中有 71% 达到了完全缓解率。此外,研究人员报告称,完全缓解的中位持续时间为 26.6 个月,部分患者的缓解时间超过 53 个月。这些发现为在有限选择的患者中持续获得治疗益处提供了进一步证据。

临床试验结果显示,63.8% 的反应者患者维持完全缓解至少 12 个月。此外,52.3% 的患者维持缓解达 24 个月,44.2% 的患者达到 36 个月的里程碑。在 FDA 审查的人群中,超过一半的反应者在 45 个月后仍维持完全缓解。

该试验还记录到反应者在 36 个月时的膀胱保留生存率为 84%。同时,疾病特异性生存率在三年后达到 98.2%,无进展生存率为 80.9%。在那些癌症从未对先前 BCG 治疗产生反应的患者中,研究人员观察到 66% 的完全缓解率。

安全性结果也支持了整个延长随访期间该疗法的临床特征。研究人员报告有 4% 的患者出现了与治疗相关的 3 级不良事件,没有发生 4 级或 5 级事件。大多数不良反应涉及与治疗给药相关的轻度或中度膀胱症状。

FDA 批准支持 ImmunityBio 扩大膀胱癌治疗范围

ImmunityBio 于 2024 年获得了 ANKTIVA 的首次 FDA 批准,为某些膀胱癌患者建立了额外的治疗选择。该批准涵盖了患有伴有原位癌的 BCG 无反应非肌层浸润性膀胱癌的成年人。随后,FDA 在 2026 年 10 月扩大了该疗法的获批适应症,包括仅患有乳头状疾病的患者。

ANKTIVA 能激活自然杀伤细胞(NK 细胞)和 T 细胞,帮助免疫系统识别并攻击癌细胞。该疗法使用白介素-15 受体激动剂来增强免疫活性并支持持久的治疗反应。

ImmunityBio 将药物直接注入膀胱内,与 BCG 联合使用,而不是通过静脉注射或皮下注射。

当患者需要手术切除膀胱时,治疗延迟可能会带来严重风险。处方信息建议医生在患者在第二次诱导疗程后未产生反应时重新考虑进行膀胱切除术。尽管取得了最新的临床进展,ImmunityBio 的股价在周五仍承压,突显了治疗发展与市场表现之间的反差。

✨ 限时优惠

获取 3 本免费股票电子书

通过专家分析,发现人工智能、加密货币和技术领域表现优异的股票。

  • AI 领域前 10 大股票 - 领先的 AI 公司
  • 加密货币前 10 大股票 - 区块链领导者
  • 科技领域前 10 大股票 - 科技巨头

Disclaimer:

All content published on this website, including hyperlinks, related applications, forums, blogs, and other media accounts, originates from third-party platforms and their users. CoinMarketInsight makes no representations or warranties of any kind regarding the website or its content. All blockchain-related data and materials are provided for informational and research purposes only and do not constitute financial, legal, or investment advice. Users and third parties are solely responsible for the content they publish. CoinMarketInsight shall not be liable for any losses arising from the use of this website. You should exercise caution and conduct your own independent research, review, analysis, and verification before making any decisions.

Read Full Article
More News
Coinokc

Coinokc

Coinokc 2025 All Rights Reserved

Copyright(C) Coinokc.com, All Rights Reserved.

Guangdong ICP License No. 2025432472-2

sitemap

Disclaimer: All content posted on this website, hyperlinks, related applications, forums, blogs, and other media accounts, as well as on other platforms and by users, originates from third-party platforms and their users. Bishitong makes no guarantees of any kind regarding the website and its content. All blockchain-related data and other content materials on the website are solely for user learning and research purposes and do not constitute advice or basis for investment, legal, or any other fields. Any content posted on this website by Bishitong users or other third-party platforms is the responsibility of the individual posting and has nothing to do with Bishitong. Bishitong is not responsible for any losses incurred due to the use of information on this website. You are advised to use relevant data and content with caution and bear all risks arising therefrom. It is strongly recommended that you independently research, review, analyze, and verify the content.

Beware of the risk of illegal fundraising under the guise of "virtual currency" and "blockchain"